SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting04-08-2023
04-08-2023
Sun Pharmaceutical Industries Results Earnings Call for Q1FY24
Conference Call with Sun Pharmaceutical Industries Ltd. Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.04-08-2023
Sun Pharma: Steady growth, but higher valuation
Higher RD expense, moderation of Revlimid opportunity, higher operational expenses and increased competitive intensity would weigh on the company in the near term. We remain on the sidelines04-08-2023
Brokerages positive on Sun Pharma's growth but investors unimpressed
Sun Pharma incurred an exceptional loss worth Rs 322.87 crore in Q1, which dragged its net profit lower. Excluding that, the company's bottomline was well above analyst expectations04-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Investor Call Audio Recording
Investor Call Audio Recording03-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per letter attached03-08-2023
Q1FY24 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries announced Q1FY24 results: Gross sales at Rs 1,17,852 million, growth of 10.7% vs Q1FY23 India formulation sales at Rs 35,604 million, up 5.1% vs Q1FY23 US formulation sales at USD 471 million, up 12% vs Q1FY23 Global specialty sales at USD 232 million, up 21% vs Q1FY23 Global specialty sales accounted for 16.2% of Q1FY24 sales Emerging markets formulation sales at USD 261 million, up 6.5% vs Q1FY23. Rest of world formulation sales at USD 195 million, up 2.6% vs Q1FY23 R&D; investments at Rs 6,796 million compared to Rs 4,608 million for Q1FY23 EBITDA at Rs 33,318 million, up 15.5% vs Q1FY23. EBITDA margin for Q1 at 27.9% vs 26.8% for Q1FY23. Adjusted net profit (excluding the exceptional items) for Q1FY24 was Rs 23,454 million, up 13.8% over Q1FY23. Reported net profit for Q1FY24 was Rs 20,225 million compared to net profit of Rs 20,609 million for Q1FY23. Dilip Shanghvi, Managing Director of the company, said, “All our business continued to have growth this quarter and we are well positioned to meet our growth guidance for FY24. US has led the revenue growth in Q1 and Global Specialty has continued to increase as a share of our revenues. I am excited about the progress in our specialty pipeline and the potential for offering new treatments for patients in need.” Result PDF03-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma reports Q1FY24 results03-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Financial Results For The Quarter Ended June 30, 2023
As per the letter attached.03-08-2023
Sun Pharma Q1 preview: Subdued growth on weak Taro numbers, muted US sales
Analysts expect a ramp-up in select specialty products to offset some impact of restrictions at Halol and Mohali plants for Sun Pharma.02-08-2023